Journal of Clinical Pediatrics ›› 2024, Vol. 42 ›› Issue (1): 63-69.doi: 10.12372/jcp.2024.22e0590
• Original Article • Previous Articles Next Articles
GENG Tian, YU Zhongsu, ZHOU Xixi, LIU Bo, ZHANG Huihua, LI Zhongyue()
Received:
2022-04-26
Online:
2024-01-15
Published:
2024-01-05
Contact:
LI Zhongyue
E-mail:lizhongyue1001@hotmail.com
GENG Tian, YU Zhongsu, ZHOU Xixi, LIU Bo, ZHANG Huihua, LI Zhongyue. Analysis of eradication effect and influencing factors of triple therapy of Helicobacter pylori in children[J].Journal of Clinical Pediatrics, 2024, 42(1): 63-69.
"
基因名称 | 引物序列(5’-3’) | 片段大小/bp |
---|---|---|
CYP*17-C | F-GCCTTAGTTTCTCAAGCCCT | 497 |
R-ACCTTTACCATTTAACCCCC | ||
CYP2C19*2 | F-GCAGGTATAAGTCTAGGAAATG | 381 |
R-TAAAGTCCCGAGGGTTGTTG | ||
CYP2C19*3 | F-CACCCTGTGATCCCACTTTC | 375 |
R-CTAATGGGCTTAGAAGCCTG | ||
cagA | F-CCTAGTCGGTAATGGGTTAT | 380 |
cagA-C | R-CCGAGATCATCAATCGTAG | |
cagA-D | R-TGCTTGATTTGCCTCATC | 396 |
vacA’s | F-ATGGAAATACAACAAACACAC | s1:259/s2:286 |
R-CTGCTTGAATGCGCCAAAC | ||
vacA’m | F-CAATCTGTCCAATCAAGCGAG | m1:567/m2:642 |
R-GCGTCTAAATAATTCCAAGG | ||
23S rRNA | F-ATGAATGGCGTAACGAGATG | 360 |
R-ACACTCAACTTGCGATTTCC |
"
项目 | 例数 | 根除[n(%)] | χ2值 | P |
---|---|---|---|---|
性别 | 2.28 | 0.131 | ||
男 | 53 | 35(66.0) | ||
女 | 56 | 29(51.8) | ||
年龄 | 4.21 | 0.122 | ||
0~6岁 | 16 | 6(37.5) | ||
6~12岁 | 66 | 43(65.2) | ||
12~18岁 | 27 | 15(55.6) | ||
内镜诊断 | 0.45 | 0.501 | ||
消化性溃疡 | 15 | 10(66.7) | ||
非溃疡疾病 | 94 | 54(57.4) | ||
黏膜病理炎症 | 0.18 | 0.912 | ||
轻度 | 29 | 18(62.1) | ||
中度 | 73 | 42(57.5) | ||
重度 | 7 | 4(57.1) | ||
vacA基因1) | 0.90 | 0.342 | ||
S1m1 | 22 | 11(50.0) | ||
S1m2 | 65 | 40(61.5) | ||
cagA基因1) | - | 1.0002) | ||
cagA-D | 86 | 50(58.1) | ||
cagA-C | 1 | 1(100) | ||
CYP2C19代谢1) | 1.70 | 0.428 | ||
慢代谢 | 12 | 9(75.0) | ||
中代谢 | 36 | 21(58.3) | ||
快代谢 | 39 | 21(53.8) |
[1] |
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report[J]. Gut, 2017, 66(1): 6-30.
doi: 10.1136/gutjnl-2016-312288 pmid: 27707777 |
[2] |
Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016)[J]. J Pediatr Gastr Nutr, 2017, 64(6): 991-1003.
doi: 10.1097/MPG.0000000000001594 |
[3] |
Lee Y, Chiang T, Chou C, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis[J]. Gastroenterology, 2016, 150(5): 1113-1124.
doi: 10.1053/j.gastro.2016.01.028 |
[4] |
O'Connor A, Furuta T, Gisbert JP, et al. Review-treatment of Helicobacter pylori infection 2020[J]. Helicobacter, 2020, 25: e12743.
doi: 10.1111/hel.v25.s1 |
[5] | 中华医学会儿科分会消化学组,《中华儿科杂志》编辑委员会. 儿童幽门螺杆菌感染诊治专家共识[J]. 中华儿科杂志, 2015, 3(7): 496-498. |
[6] |
Wang B, Lv ZF, Wang YH, et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis[J]. World J Gastroentero, 2014, 20(40): 14973-14985.
doi: 10.3748/wjg.v20.i40.14973 |
[7] | 李东丹, 周锦, 王国丽, 等. 儿童幽门螺杆菌耐药情况及影响因素分析[J]. 中华实用儿科临床杂志, 2019, 34(19): 1451-1453. |
[8] |
周颖, 王玉环, 芦军萍, 等. 上海市单中心儿童幽门螺杆菌不同治疗方案根除率及其耐药率的横断面调查[J]. 中国循证儿科杂志, 2019, 14(2): 81-86.
doi: 10.3969/j.issn.1673-5501.2019.02.001 |
[9] | 陈溢, 余金丹, 赵泓, 等. 儿童幽门螺杆菌感染根除治疗疗效分析[J]. 中国实用儿科杂志, 2018, 33(4): 291-296. |
[10] |
Seo JH, Woo HO, Youn HS, et al. Antibiotics resistance of Helicobacter pylori and treatment modalities in children with H. pylori infection[J]. Korean J Pediatr, 2014, 57(2): 67-71.
doi: 10.3345/kjp.2014.57.2.67 |
[11] |
Masumi, Okuda, Shogo, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan[J]. Pediatr Int, 2017. 59(1): 57-61.
doi: 10.1111/ped.13038 pmid: 27223686 |
[12] |
Kotilea K, Cadranel S, Salame A, et al. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children[J]. Helicobacter, 2021, 26(4): e12825.
doi: 10.1111/hel.v26.4 |
[13] |
Zhou Y, Ye Z, Wang Y, et al. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross﹕ ectional, comparative, open trial in Chinese children[J]. Helicobacter, 2020, 25(2): e12679.
doi: 10.1111/hel.v25.2 |
[14] |
Savoldi A, Carrara E, Graham D Y, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions[J]. Gastroenterology, 2018, 155(5):1372-1382.
doi: 10.1053/j.gastro.2018.07.007 |
[15] |
Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis[J]. Helicobacter, 2020, 25(4): e12692.
doi: 10.1111/hel.v25.4 |
[16] |
Song Z, Zhou L, Xue Y, et al. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial[J]. Helicobacter, 2020, 25(6): e12762.
doi: 10.1111/hel.v25.6 |
[17] |
Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection[J]. Clin Gastroenterol Hepatol, 2015, 13(5): 895-905.
doi: 10.1016/j.cgh.2014.10.036 |
[18] |
Li C, Shi Y, Suo B, et al. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: a systematic review and meta-analysis[J]. Helicobacter, 2021, 26(4): e12816.
doi: 10.1111/hel.v26.4 |
[19] | Sgouras D, Tegtmeyer N, Wessler S. Activity and functional importance of Helicobacter pylori virulence factors[J]. Adv Exp Med Biol, 2019, 1149: 35-56. |
[20] |
Sharndama HC, Mba IE. Helicobacter pylori: An up-to-date overview on the virulence and pathogenesis mechanisms[J]. Braz J Microbiol, 2022, 53(1): 33-50.
doi: 10.1007/s42770-021-00675-0 pmid: 34988937 |
[21] |
Wang D, Li Q, Gong Y, et al. The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: a meta-analysis[J]. PLoS One, 2017, 12(5): e0177455.
doi: 10.1371/journal.pone.0177455 |
[22] |
Zhang SH, Zhu X, Li BM, et al. The effect of virulence genotypes of Helicobacter pylori on eradication therapy in children[J]. Saudi J Gastroenterol, 2018, 24(4): 249-254.
doi: 10.4103/sjg.SJG_579_17 |
[23] |
López-Góngora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection[J]. J Antimicrob Chemoth, 2015, 70(9): 2447-2455.
doi: 10.1093/jac/dkv155 |
[24] |
Cosme A, Montes M, Ibarra B, et al. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance[J]. World J Gastroentero, 2017, 23(18): 3367-3373.
doi: 10.3748/wjg.v23.i18.3367 |
[25] |
Gong EJ, Ahn JY, Kim JM, et al. Genotypic and phenotypic resistance to clarithromycin in Helicobacter pylori strains[J]. J Clin Medicine, 2020, 9(6): 1930.
doi: 10.3390/jcm9061930 |
[26] | 吕秋菊, 李秀英, 刘欢, 等. 中国人群中 CYP2C19 基因多态性对质子泵抑制剂三联疗法根除幽门螺杆菌疗效影响的meta分析[J]. 中国医院药学杂志, 2017, 37(11): 1097-1103. |
[27] |
Arévalo Galvis A, Trespalacios Rangel AA, Otero Regino W. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy[J]. Helicobacter, 2019, 24(3): e12574.
doi: 10.1111/hel.2019.24.issue-3 |
[28] |
Graham DY, Dore MP. Update on the use of vonoprazan: a competitive acid blocker[J]. Gastroenterology, 2018, 154(3): 462-466.
doi: S0016-5085(18)30030-1 pmid: 29337157 |
[29] |
Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phaseⅢ, randomised, double-blind study[J]. Gut, 2016, 65(9): 1439-1446.
doi: 10.1136/gutjnl-2015-311304 |
[30] |
Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori[J]. Helicobacter, 2018, 23(4): e12495.
doi: 10.1111/hel.2018.23.issue-4 |
[1] | YAO Qianghua, WANG Yingchao, WANG Dao, LIU Yufeng. Analysis of risk factors for early death of acute promyelocytic leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(1): 53-57. |
[2] | JIN Mei, LIU Jing, LIU Kang, ZHAO Libo, ZHAO Ziwei, SUN Suzhen. Characteristics of neurofilament light chain levels in cerebrospinal fluid of Guillain-Barre syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(1): 58-62. |
[3] | ZHAO Fangyuan, CHEN Yonghua, WANG Kana, WANG Chunlin. Analysis of correlation between Turner syndrome karyotype and autoimmune thyroid disease [J]. Journal of Clinical Pediatrics, 2024, 42(1): 70-74. |
[4] | DAI Yinliang, HE Hailong, FAN Liyan, LI Jie, LU Jun, XIAO Peifang, LING Jing, ZHENG Jiajia, DU Zhizhuo, HU Shaoyan. Successful rescue of progression from Fanconi anemia to acute myeloid leukemia by allogeneic hematopoietic stem cell transplantation with decitabine maintenance: a case report [J]. Journal of Clinical Pediatrics, 2024, 42(1): 75-79. |
[5] | ZOU Liping. Childhood encephalopathy: a group of diseases associated with various diseases [J]. Journal of Clinical Pediatrics, 2023, 41(9): 641-643. |
[6] | ZHANG Weihua, ZOU Liping, REN Haitao, GUAN Hongzhi. Beware of the pitfalls in diagnosis and treatment of autoimmune encephalitis in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 644-649. |
[7] | HOU Chi, CHEN Wenxiong, LIAO Yinting, WU Wenxiao, TIAN Yang, ZHU Haixia, PENG Bingwei, ZENG Yiru, WU Wenlin, CHEN Zongzong, LI Xiaojing. Clinical analysis of autoimmune glial fibrillary acidic protein astrocytopathy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 656-660. |
[8] | YANG Yating, CAI Yuehao, FANG Qiong, CHEN Lang, CHEN Qiaobin, LIN Zhi, WU Feifei, LIN Meng. Clinical analysis of idiopathic and symptomatic occipital lobe epilepsy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 668-673. |
[9] | HOU Ruolin, WU Jing, LI Ling. Pediatric autoimmune encephalitis with brain MRI showing meningeal thickening and enhancement [J]. Journal of Clinical Pediatrics, 2023, 41(9): 674-679. |
[10] | WU Yuefang, SUN Yanling, WU Wanshui, DU Shuxu, LI Miao, SUN Liming. Analysis of prognostic factors and survival status of group 4 medulloblastoma in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 686-691. |
[11] | SUN Juan, LI Haiying, JIA Peisheng, WANG Huaili. Clinical analysis of fulminant myocarditis in 12 children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 692-696. |
[12] | Reviewer: WANG Chenhui, Reviser: YANG Hui. Research progress on early screening and diagnosis of Crohn's disease in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 708-714. |
[13] | SHEN Nan, DU Bailu. Strategies for the diagnosis, treatment, and management of invasive fungal infections in children with hematologic neoplasms [J]. Journal of Clinical Pediatrics, 2023, 41(8): 571-577. |
[14] | XU Beixue, LIU Quanbo. Clinical analysis of 195 children with invasive pulmonary fungal infection [J]. Journal of Clinical Pediatrics, 2023, 41(8): 584-588. |
[15] | CHEN Hongyu, LIU Zihao, WANG Heping, LIAO Cuijuan, LI Li, WANG Wenjian, LAI Jianwei. Role of nontypeable Haemophilus influenzae biofilms in chronic pulmonary infection in children [J]. Journal of Clinical Pediatrics, 2023, 41(8): 589-593. |
|